About MBX 1416 MBX 1416 is an investigational long-acting glucagon-likepeptide-1 (GLP-1) receptor antagonist in development as a potential treatment for PBH. It was designed using the Company’s ...
In the international SUMMIT trial, adults with heart failure preserved ejection fraction (HFpEF) and obesity taking tirzepatide for up to 3 years had a reduced combined risk of worsening heart failure ...